Bend Harm Reduction Talk

46
Harm Reduction Strategies for Chronic Pain Patients Paul C. Coelho, MD Board Certified PM&R Subspecialty Certified Pain Medicine

Transcript of Bend Harm Reduction Talk

Page 1: Bend Harm Reduction Talk

Harm Reduction Strategies for Chronic

Pain Patients

Paul C. Coelho, MD Board Certified PM&R

Subspecialty Certified Pain Medicine

Page 2: Bend Harm Reduction Talk

Disclosures

Paul Coelho,MD: No industry financial relationships to disclose. I am a member of the OPG planning committee and on the OPG speakers bureau.

Page 3: Bend Harm Reduction Talk

Table Of Contents

1. Opioid Overdose Deaths (ODD)

2. 2016 CDC Opioid Guidelines

3. Risk Factors for an ODD

4. Risk Factors for Opioid Use Disorder (Addiction)

5. Harm Reduction Strategies

6. Sample Cases

Page 4: Bend Harm Reduction Talk

0

12500

25000

37500

50000

198019821984198619881990199219941996199820002002200420062008201020122014

US Opioid Overdose Deaths 1980-2014Peak Incidence of Prescription ODD Age 45-54*

Page 5: Bend Harm Reduction Talk

Death Rates 2000- 2015

http://www.pnas.org/content/112/49/15078.full.pdf

Page 6: Bend Harm Reduction Talk

0

12500

25000

37500

50000

1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014

Injection Increases Vs Opioid ODD

0

100

200

300

Opioid Overdose Deaths Increased 250%

Spinal Injections Increased 375%

Page 7: Bend Harm Reduction Talk

2016 CDC Guidelines

https://www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glance-a.pdf

Page 8: Bend Harm Reduction Talk

2016 CDC Guidelines

https://www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glance-a.pdf

Page 9: Bend Harm Reduction Talk

Mandatory PDMP Use

http://content.healthaffairs.org/content/35/10/1876.abstract

Page 10: Bend Harm Reduction Talk

Risk Factors for Overdose Death

1. Opioid Dose 2. Methadone 3. Opioids + Benzodiazepines/Sedative

Page 11: Bend Harm Reduction Talk

Dose as a Risk Factor For ODD

https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/2.Quality_Improvement/2.Patient_Safety/2.Patient_Safety_Education/C171%20-%20Franklin.pdf

Page 12: Bend Harm Reduction Talk

Methadone as a Risk Factor for ODD

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5.htm

1/3rd of all ODD

Page 13: Bend Harm Reduction Talk

Co-Rx’d Benzos as a Risk Factor for ODD

http://www.ncbi.nlm.nih.gov/pubmed/26890165

1/3rd of all ODD

Page 14: Bend Harm Reduction Talk

Risk Factors for Opioid Use Disorder

1. Age 2. Length of Exposure 3. Dose 4. Psychosocial Factors: a. H/o drug/alcohol tobacco abuse b. Family hx of drug/alcohol abuse c. H/o childhood trauma/abuse d. Intercurrent mental health ds

Page 15: Bend Harm Reduction Talk

Prescribed Opioid Addiction Tx By Age

http://www.samhsa.gov/data/sites/default/files/2013_Treatment_Episode_Data_Set_National/2003_2013_Treatment_Episode_Data_Set_National_Body.html

2013

Page 16: Bend Harm Reduction Talk

Opioid Use Disorder Dx By Age

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032801/

0

10

20

30

40

18-30 31-40 41-50 51-64 >65

N = 570K

Page 17: Bend Harm Reduction Talk

OR Medicaid Opioid Rx’s By Age (86% 18-60yrs)

http://www.ncbi.nlm.nih.gov/pubmed/26766755

0

22.5

45

67.5

90

18-39 40-59 60-79 >80

Top 10% Prescribers Rx’d 80% All Opioids

Page 18: Bend Harm Reduction Talk

Dose & Length of Exposure As Risk Factors For OUD

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032801/

Low Dose 0-36MED Med Dose 37-120MED High Dose > 120MED

Page 19: Bend Harm Reduction Talk

Harm Reduction Strategies

Page 20: Bend Harm Reduction Talk

Identify At Risk Patients

1. Morphine Equivalent Dose > 120mg/day 2. Methadone 3. Opioid and co-prescribed benzodiazepine 4. H/o aberrant behavior or addiction

Page 21: Bend Harm Reduction Talk

Prescription Drug Monitoring Program

http://www.orpdmp.com/health-care-provider/

Page 22: Bend Harm Reduction Talk

Prescription Drug Monitoring Program

http://www.orpdmp.com/health-care-provider/

Page 23: Bend Harm Reduction Talk

PDMP Dashboard

https://orpdmp-ph.hidinc.com/orlogappl/bdorpdmqlog/pmqhome.html

6mo Look Back

Page 24: Bend Harm Reduction Talk

Coelho’s PDMP Dashboard

https://orpdmp-ph.hidinc.com/orlogappl/bdorpdmqlog/pmqhome.html

Patient Name Dose >120 MED

Methadone Benzodiazepine >90 Days Use > 4 Pharmacies/Prescribers

167 39 (23%) 4 (2%) 98 (59%) 79 (47%) 4 (2%)

Page 25: Bend Harm Reduction Talk

Opioid Dose Calculator

http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm

Page 26: Bend Harm Reduction Talk

Examples of 120MED

Fentanyl 50ucg/hr

Buprenorphine 4mg

Methadone 30mg

Hydromorphone 30mg

Oxycodone 80mg

Oxymorphone 40mg

Morphine 120mg

Codeine 800mg

Page 27: Bend Harm Reduction Talk

MED > 90 Prescribe Nasal Naloxone

1. SB 384 legalized for lay administration in 2013.

2. Stock in your pharmacies. 3. Some patients must pay out of

pocket ($35.00 -$75.00)

http://www.amphastar.com/assets/naloxone.pdf

Page 28: Bend Harm Reduction Talk

Consider a Data 2000 Waiver: Buprenorphine

http://projects.huffingtonpost.com/dying-to-be-free-heroin-treatment/opioid-abuse-outpace-treatment-capacity

17K MD/DO in OR, 400 with Waiver [2%]

Page 29: Bend Harm Reduction Talk

Buprenorphine

1. Schedule III drug, partial mu agonist 2. FDA approved for both pain - Butrans/Belbuca - and addiction - Suboxone/Subutex. 3. Ceiling effect for respiratory suppression (RS).

Page 30: Bend Harm Reduction Talk

Buprenorphine’s Ceiling Effect for R.S.

Page 31: Bend Harm Reduction Talk

Buprenorphine & ODD

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5.htm

Page 32: Bend Harm Reduction Talk

Buprenorphine Substitution for High Dose Opioids

http://www.ncbi.nlm.nih.gov/pubmed/25220043

Page 33: Bend Harm Reduction Talk

Buprenorphine Is A Powerful Analgesic

http://www.compoundchem.com/2014/09/25/painkillers/

Page 34: Bend Harm Reduction Talk

Random Urine Or Saliva Drug Screening

https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm

Page 35: Bend Harm Reduction Talk

Sample Cases

Page 36: Bend Harm Reduction Talk

Case 1: Teresa

75y/o retiree with diffuse OA. Lives alone in Prineville. Uses Oxycodone-APAP 10/325, five perday (MED 70). No h/o aberrant behavior or addiction.

Page 37: Bend Harm Reduction Talk

Case 1: Teresa

Teresa reports that the medications give her comfort. She was started on her current dose years ago.

Recommendations: Continue as prescribed.

Page 38: Bend Harm Reduction Talk

Case 2: Cleatus

68y/o retired logger with failed back surgery syndrome. Lives with spouse Rx’d Methadone 10mg po QID (MED 320). No h/o addiction or aberrant behaviors.

Page 39: Bend Harm Reduction Talk

Case 2: Cleatus

Recommendations: Call Cleatus & his spouse in. Explain that his dose and medication are both unsafe and will need to change. a. Prescribe nasal naloxone & train spouse in assembly and use. b. Offer a conversion to Morphine Sulfate ER 75mg QD (30,15,30) at his next refill.

http://www.prescribetoprevent.org/wp-content/uploads/2012/11/naloxone-one-pager-in-nov-2012.pdf

Page 40: Bend Harm Reduction Talk

Case 3: Jane

55y/o woman with FMS. Lives alone in Redmond. Uses OxyContin 30mg PO BID (MED 80), and alprazolam 0.5mg po QID. No h/o aberrant behavior or addiction.

Page 41: Bend Harm Reduction Talk

Case 3: JaneRecommendations: Call Jane in to clinic. Explain that the combination of alprazolam and Oxycodone is unsafe. a. Offer a conversion to clonazapam 2mg BID. b. Taper clonazepam by .5 -1mg/mo over 4-8mo. c. Offer non-benzodiazepine alternatives for anxiety/sleep/panic attacks.

http://www.slideshare.net/101N/alternatives-to-benzodiazepines-60678319

Page 42: Bend Harm Reduction Talk

Case 4: Luc

49y/o married restaurant owner with chronic migraine. Prescribed Oxycodone 5mg BID, 30/mo over many years. No h/o addiction or aberrant behavior. Recent review of the PDMP with at a f/u visit reveals visits to 6 other prescribers over the past 3mo for opioids. Patient acknowledges that he is overusing pain medication and wants your help in getting off opioids entirely.

Page 43: Bend Harm Reduction Talk

Case 4: Luc

Recommendations: Use your data-2000 waiver to offer Luc treatment of opioid use disorder. Stop opioids. a. Offer conversion to buprenorphine

(Suboxone/Subutex) with a planned 6mo taper off. (8mg QD x 2mo, 4mgQD x 2mo, 4mg QOD x 2mo)

b. Offer an addiction counseling referral.

c. Continue to see frequently for followups with both urine or saliva drug screens and frequent checks of the PDMP to ensure adherence.

Page 44: Bend Harm Reduction Talk

Help with Tough Cases

Page 45: Bend Harm Reduction Talk

ResourcesAlternatives to Benzodiazepines: http://www.slideshare.net/101N/alternatives-to-benzodiazepines-60701295

Oregon Prescription Drug Monitoring Signup: http://www.orpdmp.com/health-care-provider/

Opioid Withdrawal Attenuation Cocktail: http://www.slideshare.net/101N/opioid-withdrawal-attenuation-coctail

Nasal Naloxone: http://www.amphastar.com/assets/naloxone.pdf http://www.narcannasalspray.com/nns-4-mg-dose/how-to-use-nns/

Oregon Drug & Alcohol Services by County: https://www.oregon.gov/oha/amh/publications/provider-directory.pdf